Tim-3, a negative regulator of anti-tumor immunity

Current Opinion in Immunology

Volumn 24, Issue 2, 2012, Pages 213-216

  Anderson, Ana Carrizosa ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 2; IPILIMUMAB; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE IMMUNOGLOBULIN 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOIMMUNE DISEASE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE MODEL; DRUG TARGETING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NONHUMAN; PROGNOSIS; REVIEW; TH1 CELL; TUMOR ENGRAFTMENT; TUMOR IMMUNITY;

ANIMALS; HUMANS; IMMUNOTHERAPY; MEMBRANE PROTEINS; NEOPLASMS; RECEPTORS, VIRUS; T-LYMPHOCYTES;

EID: 84859157752     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2011.12.005     Document Type: Review

References (28)

1. Monney L., Sabatos C.A., Gaglia J.L., Ryu A., Waldner H., Chernova T., Manning S., Greenfield E.A., Coyle A.J., Sobel R.A., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415:536-541.
2. Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., Zheng X.X., Strom T.B., Kuchroo V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005, 6:1245-1252.
3. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-3 PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010, 207:2187-2194.
4. Zhou Q., Munger M.E., Veenstra R.G., Weigel B.J., Hirashima M., Munn D.H., Murphy W.J., Azuma M., Anderson A.C., Kuchroo V.K., et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011, 117:4501-4510.
5. Fourcade J., Sun Z., Benallaoua M., Guillaume P., Luescher I.F., Sander C., Kirkwood J.M., Kuchroo V., Zarour H.M. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010, 207:2175-2186.
6. Baitsch L., Baumgaertner P., Devevre E., Raghav S.K., Legat A., Barba L., Wieckowski S., Bouzourene H., Deplancke B., Romero P., et al. Exhaustion of tumor-specific CD8 T cells in metastases from melanoma patients. J Clin Invest 2011, 121:2350-2360.
7. Dardalhon V., Anderson A.C., Karman J., Apetoh L., Chandwaskar R., Lee D.H., Cornejo M., Nishi N., Yamauchi A., Quintana F.J., et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J. Immunol 2010, 185:1383-1392.
8. Zhang Y., Ma C.J., Wang J.M., Ji X.J., Wu X.Y., Moorman J.P., Yao Z.Q. Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes. J Leukoc Biol 2011, (Epub ahead of print).
9. Jan M., Chao M.P., Cha A.C., Alizadeh A.A., Gentles A.J., Weissman I.L., Majeti R. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A 2011, 108:5009-5014.
10. Kikushige Y., Shima T., Takayanagi S., Urata S., Miyamoto T., Iwasaki H., Takenaka K., Teshima T., Tanaka T., Inagaki Y., et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010, 7:708-717.
11. Huang X., Bai X., Cao Y., Wu J., Huang M., Tang D., Tao S., Zhu T., Liu Y., Yang Y., et al. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med 2010, 207:505-520.
12. Zajac A.J., Blattman J.N., Murali-Krishna K., Sourdive D.J., Suresh M., Altman J.D., Ahmed R. Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 1998, 188:2205-2213.
13. Wherry E.J. T cell exhaustion. Nat Immunol 2011, 12:492-499.
14. Wherry E.J., Blattman J.N., Murali-Krishna K., van der Most R., Ahmed R. Viral persistence alters CD8-T cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003, 77:4911-4927.
15. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
16. Blank C., Kuball J., Voelkl S., Wiendl H., Becker B., Walter B., Majdic O., Gajewski T.F., Thoebald M., Andreesen R., et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 2006, 119:317-327.
17. Mumprecht S., Schurch C., Schwaller J., Solenthaler M., Ochsenbein A.F. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009, 114:1528-1536.
18. Ahmadzadeh M., Johnson L.A., Heemskerk B., Wunderlich J.R., Dudley M.E., White D.E., Rosenberg S.A. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
19. Gehring A.J., Ho Z.Z., Tan A.T., Aung M.O., Lee K.H., Tan K.C., Lim S.G., Bertoletti A. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2009, 137:682-690.
20. Yamamoto R., Nishikori M., Kitawaki T., Sakai T., Hishizawa M., Tashima M., Kondo T., Ohmori K., Kurata M., Hayashi T., et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008, 111:3220-3224.
21. Ngiow S.F., von Scheidt B., Akiba H., Yagita H., Teng M.W., Smyth M.J. Anti-TIM3 antibody promotes T cell IFN-{gamma}-mediated anti-tumor immunity and suppresses established tumors. Cancer Res 2011, 71:6567-6571.
22. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
23. Anderson A.C., Anderson D.E., Bregoli L., Hastings W.D., Kassam N., Lei C., Chandwaskar R., Karman J., Su E.W., Hirashima M., et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007, 318:1141-1143.
24. Nakayama M., Akiba H., Takeda K., Kojima Y., Hashiguchi M., Azuma M., Yagita H., Okumura K. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 2009, 113:3821-3830.
25. DeKruyff R.H., Bu X., Ballesteros A., Santiago C., Chim Y.L., Lee H.H., Karisola P., Pichavant M., Kaplan G.G., Umetsu D.T., et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol 2010, 184:1918-1930.
26. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
27. Berger R., Rotem-Yehudar R., Slama G., Landes S., Kneller A., Leiba M., Koren-Michowitz M., Shimoni A., Nagler A. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008, 14:3044-3051.
28. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., Stankevich E., Pons A., Salay T.M., McMiller T.L., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28:3167-3175.